TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major heart study aims to tame deadly protein buildup
Disease control Recruiting nowThis large, late-stage study is testing whether a new medicine, NNC6019-0001, can help people with a serious heart condition called ATTR-CM. The condition is caused by a harmful protein building up in the heart. Researchers will see if the drug can lower the risk of heart-related…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Massive 2,000-Patient study tracks new heart drug in everyday use
Knowledge-focused Recruiting nowThis study aims to understand how a recently approved medication called acoramidis works for patients with ATTR amyloidosis cardiomyopathy in real-world settings, outside of controlled clinical trials. Researchers will observe up to 2,000 adults across Europe who are starting thi…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC